Buy Perjeta 420 mgI14 mL injaction

Buy Perjeta 420 mgI14 mL injaction is indicated for the treatment of HER2 positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer^[1,2,3].

How does Perjeta (pertuzumab) work?

Perjeta (pertuzumab) is used in combination with trastuzumab and docetaxel (other cancer medicines) for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease^1,2,3.It is also used in combination with trastuzumab and chemotherapy as neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen for early breast cancer^1,2,3.

Is Perjeta (pertuzumab) approved?

Perjeta (pertuzumab) was approved for HER2 positive breast cancer in metastatic patients or as neoadjuvant therapy by:

• FDA (USA) on June 12, 2012^[5]
• EMA (EU) on March 4, 2013^[2]
• TGA (AUS) on May 6, 2013^[3]
• Health Canada on May 8, 2013^[7]
• Medsafe (New Zealand) on July 18, 20134

  Common side effects of Perjeta (pertuzumab)The most common side effects with Perjeta given with trastuzumab and chemotherapy are⁴:

  • diarrhoea
  • alopecia (hair loss)
  • nausea
  • neutropenia (low levels of neutrophils, a type of white blood cell important for fighting infections).

  Serious side effects of Perjeta (pertuzumab)

  The most common serious side effects include⁴:

  • febrile neutropenia (low levels of neutrophils with fever)
  • serious diarrhoea
  • leucopenia (low white blood cell counts)
  • neutropenia.

  .